ArticleObstetrics and gynecology2017
Placental Complications Associated With Psychostimulant Use in Pregnancy.
Article in Obstetrics and gynecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Maternal and offspring outcomes associated with prescribed ADHD medication in pregnancy: a systematic review.Archives of women's mental health · 2025Pooled it
- In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders - a population-based cohort study and meta-analysis.Molecular psychiatry · 2025Pooled it
- Associations of Prescribed ADHD Medication in Pregnancy with Pregnancy-Related and Offspring Outcomes: A Systematic Review.CNS drugs · 2020Pooled it
- Exploring the association between maternal attention-deficit/hyperactivity disorder and obstetric complications: a danish population-based register study.Social psychiatry and psychiatric epidemiology · 2026Article
- Attention-deficit/hyperactivity disorder medication use and cardiometabolic conditions in pregnancy: a population-based cohort study.Archives of women's mental health · 2026Article
- Fetal Growth Restriction, Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder-Connecting the Dots: A Narrative Review.Children (Basel, Switzerland) · 2025Review
- Review
- Microbial Interconnections in One Health: A Critical Nexus Between Companion Animals and Human Microbiomes.Microorganisms · 2025Review
- Comparing Obstetrical Outcomes Between Attention Deficit Hyperactivity Disorder and Attention Deficit Disorder: A Population-Based Studys.Journal of clinical medicine · 2025Article
- Pathologies in a preterm infant exposed to methamphetamine in utero: Case report and literature review.Radiology case reports · 2025Article
- Bioethical evaluation of methylphenidate and atomoxetine for pediatric ADHD and cognitive enhancement.Philosophy, ethics, and humanities in medicine : PEHM · 2025Article
- Investigating maternal and neonatal health outcomes associated with continuing or ceasing dexamphetamine treatment for women with attention-deficit hyperactivity disorder during pregnancy: a retrospective cohort study.Archives of women's mental health · 2024Article
- Prescription psychostimulant use, admissions and treatment initiation and retention in pregnant people with opioid use disorder.Nature. Mental health · 2024Article
- The State of Use and Utility of Negative Controls in Pharmacoepidemiologic Studies.American journal of epidemiology · 2024Review
- Substance use before or during pregnancy and the risk of child mortality, perinatal morbidities and congenital anomalies.Epidemiology and psychiatric sciences · 2023Article
- In utero exposure to ADHD medication and long-term offspring outcomes.Molecular psychiatry · 2023Article
- The association between psychostimulant use in pregnancy and adverse maternal and neonatal outcomes: results from a distributed analysis in two similar jurisdictions.International journal of epidemiology · 2023Article
- Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019.European journal of clinical pharmacology · 2023Article
- A Bayesian latent class model for predicting gestational age in health administrative data.Pharmaceutical statistics · 2022Article
- Characteristics of Prescription Opioid Analgesics in Pregnancy and Risk of Neonatal Opioid Withdrawal Syndrome in Newborns.JAMA network open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo evaluate whether psychostimulants used to treat attention-deficit/hyperactivity disorder (ADHD) are associated with risk of adverse placental-associated pregnancy outcomes including preeclampsia, placental abruption, growth restriction, and preterm birth.
methodsWe designed a population-based cohort study in which we examined a cohort of pregnant women and their liveborn neonates enrolled in Medicaid from 2000 to 2010. Women who received amphetamine-dextroamphetamine or methylphenidate monotherapy in the first half of pregnancy were compared with unexposed women. We considered atomoxetine, a nonstimulant ADHD medication, as a negative control exposure. To assess whether the risk period extended to the latter half of pregnancy, women who continued stimulant monotherapy after 20 weeks of gestation were compared with those who discontinued. Risk ratios and 95% CIs were estimated with propensity score stratification to control for confounders.
resultsPregnancies exposed to amphetamine-dextroamphetamine (n=3,331), methylphenidate (n=1,515), and atomoxetine (n=453) monotherapy in early pregnancy were compared with 1,461,493 unexposed pregnancies. Among unexposed women, the risks of the outcomes were 3.7% for preeclampsia, 1.4% for placental abruption, 2.9% for small for gestational age, and 11.2% for preterm birth. The adjusted risk ratio for stimulant use was 1.29 for preeclampsia (95% CI 1.11-1.49), 1.13 for placental abruption (0.88-1.44), 0.91 for small for gestational age (0.77-1.07), and 1.06 for preterm birth (0.97-1.16). Compared with discontinuation (n=3,527), the adjusted risk ratio for continuation of stimulant use in the latter half of pregnancy (n=1,319) was 1.26 for preeclampsia (0.94-1.67), 1.08 for placental abruption (0.67-1.74), 1.37 for small for gestational age (0.97-1.93), and 1.30 for preterm birth (1.10-1.55). Atomoxetine was not associated with the outcomes studied.
conclusionPsychostimulant use during pregnancy was associated with a small increased relative risk of preeclampsia and preterm birth. The absolute increases in risks are small and, thus, women with significant ADHD should not be counseled to suspend their ADHD treatment based on these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.